Volume 2.18 | May 11

Mesenchymal Cell News 2.18, May 11, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Deficiency in p53 but Not Retinoblastoma Induces the Transformation of Mesenchymal Stem Cells In Vitro and Initiates Leiomyosarcoma In Vivo
In this study, researchers evaluated the potential oncogenic effects of p53 and/or retinoblastoma deficiency in mesenchymal stem cell transformation and sarcomagenesis. [Cancer Res]

MethoCult®  
MethoCult®
The most published medium for hematopoietic CFC assays

by STEMCELL Technologies
 
 
TEST YOUR COLONY IDENTIFICATION SKILLS STEMCELL Technologies Inc
 


SCIENCE NEWS

Cytori Reports Stem & Regenerative Cells From Body Fat Produce Statistically Significant Improvement in Heart Function In Chronic Ischemia Trial
The first clinical trial of adipose tissue-derived stem and regenerative cells for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients’ aerobic capacity measured as metabolic equivalents; and reduced the extent of infarct size in the left ventricle. [Cytori Therapeutics Press Release]

TCA Cellular Presents Promising Adult Stem Cells Treatment In Heart Attack Victims At SCAI Conference
TCA Cellular Therapy’s Medical Director Gabriel Lasala, M.D. presents advances in a proprietary combination adult stem cell treatment for acute myocardial infarction at a scientific conference in San Diego. [Press release from Medical News Today discussing research presented at the Society for Cardiovascular Angiography and Interventions]

MesenCult®-XF Medium  
Culture Human Mesenchymal Stem Cells in
Xeno-Free MesenCult®-XF

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 


CURRENT PUBLICATIONS (Ranked by Impact Factor)

Cyclooxygenase-2 Controls Energy Homeostasis in Mice by De Novo Recruitment of Brown Adipocytes
Studying mouse models, researchers show that cyclooxygenase (COX)-2, a rate-limiting enzyme in prostaglandin (PG) synthesis, is a downstream effector of beta-adrenergic signaling in white adipose tissue (WAT) and is required for the induction of brown adipose tissue in WAT depots. PG shifted the differentiation of defined mesenchymal progenitors toward a brown adipocyte phenotype. [ Science]

Engineered Mesenchymal Stem Cells with Self-Assembled Vesicles for Systemic Cell Targeting
These results show that the transitory modification of cell surfaces with lipid vesicles can be used to efficiently immobilize adhesion ligands and potentially target systemically administered cells to the site of inflammation. [Biomaterials]

Pbx1 Represses Osteoblastogenesis by Blocking Hoxa10-Mediated Recruitment of Chromatin Remodeling Factors
Here researchers have established that Pbx1 negatively regulates Hoxa10-mediated gene transcription in mesenchymal cells and identified components of a Pbx1 complex associated with genes in osteoblasts. [Mol Cell Biol]

Human Mesenchymal Stem Cells Inhibit Vascular Permeability by Modulating VE-Cadherin/Beta-Catenin Signaling
Researchers show that mesenchymal stem cells significantly reduce endothelial permeability in co-cultured HUVECs, and following exposure to vascular endothelial growth factor, a potent barrier permeability-enhancing agent. [Stem Cells Dev]

Changes in the Expression Pattern of Mesenchymal and Pluripotent Markers in Human Adipose-Derived Stem Cells
Researchers examine here the expression pattern of mesenchymal and pluripotent markers in human adipose-derived stem cells during culture. [Cell Biol Int]


INDUSTRY NEWS

Osiris Therapeutics Receives FDA Orphan Drug Designation for Stem Cell Treatment for Type 1 Diabetes
Osiris Therapeutics, Inc. announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. [Osiris Therapeutics, Inc. Press Release]

Power3 Principals Patent Stem Cell Breakthrough Identifying Protein Biomarkers Which Scientists Expect to be the Gold Standard for Future Stem Cell Therapy
StemTroniX, Inc. and Power3 Medical Products, Inc. announced that a joint provisional patent application entitled, “Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy” has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office. [Power3 Medical Products, Inc. Press Release]

Details of New Wellcome Trust Investigator Awards Announced
The Wellcome Trust announced further details of its Investigator Awards, a major new scheme to support world-class researchers to tackle ambitious research questions about health and disease. [The Wellcome Trust Press Release]

Vitro Forms Strategic Alliance With a Leading Stem Cell Company
Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it signed a contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix®, Inc., a leading firm known for its pioneering analysis of stem cells. [Marketwire]

POLICY NEWS

NIH Starts to Flesh out Drug Development Program
Lawmakers began discussing the details of a newly created drug development program at the National Institutes of Health (NIH). NIH Director Francis Collins told a Senate panel that he’s eager to get started-once the program has a budget. [National Institutes of Health, United States]

Notice of Funding Opportunity for a Cell Characterization Core for the National Heart, Lung and Blood Institute Progenitor Cell Biology Consortium (NOT-HL-10-109) [National Institutes of Health, United States]

Notice of Intent to Publish Request for Applications for the Blood and Marrow Transplant Clinical Trials Network Data Coordinating Center (U10) (NOT-HL-10-108) [National Institutes of Health, United States]

Enhancing Peer Review: Expectation for Service on NIH Peer Review and Advisory Groups (NOT-OD-10-089) [National Institutes of Health, United States]

Request for Information: Scientific and Regulatory Issues to be Explored at an Upcoming Pluripotent Stem Cell Workshop Involving NIH and FDA (NOT-NS-10-016) [National Institutes of Health, United States]

Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket No. FDA-2010-N-0184) [Food and Drug Administration, United States]

Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety and Quantitative Risk Assessment: Blood Safety and Availability; Public Workshops (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]


EVENTS

European Molecular Biology Laboratory (EMBL) Stem Cells, Tissue Homeostasis and Cancer Conference
May 12-15, 2010
Heidelberg, Germany

16th Annual International Society for Cellular Therapy (ISCT) Meeting
May 23-26, 2010
Philadelphia, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – European Union 2010
June 13-17, 2010
Galway, Ireland

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) 3rd Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

5th World Congress on Preventative and Regenerative Medicine (WCRM) 2010
October 5-7, 2010
Hannover, Germany

2010 American Society for Matrix Biology (ASMB) Meeting
October 24-27, 2010
Charleston, United States

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America 2010 Annual Conference
December 5-8, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



JOB OPPORTUNITIES



Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Sr. Product Support and Training Specialist (CardianBCT)

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Mesenchymal Cell News.

Visit here to post your career opportunities.



Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!





Learn more about Mesenchymal Cell News: Archives  |  Events  |  Subscribe  |  Contact Us